🧬 Better outcomes: immune-enriched, proliferative tumors
🚫 Poor prognosis: angiogenic, fibrotic, immune-excluded TMEs + PIK3CA alterations
🔄 Early resistance signals include PD-L1 downregulation and immunosuppressive macrophage infiltration

IMMUcan’s strength lies in its community — brilliant minds united to turn complex data into patient impact.

Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌

#IMMUcan #Collaboration #DataScience

Highlights included:
🔹 New molecular, cellular & clinical data — from spatial transcriptomics to plasma profiling
🔹 Cohort updates across breast, colorectal, renal, lung & head & neck cancers
🔹 Multi-modal data integration linking spatial & bulk omics

✅ ASCO: Athenais van der Elst presented multi-omics data on resistance to anti-PD1 in head & neck cancer. Promising signal for B2M as a predictive biomarker.

✅ AACR: Marie Morfouace & Henoch Hong explored how tumours evade immune response, sharing insights on targeting immune suppression in solid cancers.